What is Polaryx Therapeutics, Inc. 's G&A?

Polaryx Therapeutics, Inc. (PLYX) reported G&A of $1.28M in Q1 2026.

How has Polaryx Therapeutics, Inc. 's G&A changed year-over-year?

Polaryx Therapeutics, Inc. 's G&A increased by 280.7% year-over-year, from $336K to $1.28M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Polaryx Therapeutics, Inc. PLYX G&A

G&A at other companies

Eton Pharmaceuticals, Inc.ETON

$10.45M+13.9%

Relay Therapeutics, Inc.RLAY

$11.03M-41.2%

PVL

Palvella TherapeuticsPVLA

$5.52M+45.4%

Segments

By segment

See full

Lysosomal Storage Disorders$812K+142%

Other financials

Income statement

See full

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Balance sheet

See full

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Cash flow

See full

Operating cash flow-$2.1M-191%

Valuation

See full

Market cap$132.59M-87.6%

Returns & leverage

See full

Return on equity-1,209.8%—

Current ratio3.5×—

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's G&A?: Polaryx Therapeutics, Inc. (PLYX) reported G&A of $1.28M in Q1 2026.
How has Polaryx Therapeutics, Inc. 's G&A changed year-over-year?: Polaryx Therapeutics, Inc. 's G&A increased by 280.7% year-over-year, from $336K to $1.28M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.